Our Investment in Eli
It’s no secret that women’s reproductive hormones dictate so much of what goes on in their bodies, from the onset of menstruation, to ongoing ovulation and eventually driving menopause.
I clearly remember the first time I met Marina Pavlovic Rivas, co-founder and CEO of Eli.
The company was fresh out of Techstars and Marina was pitching me on the vision for the company. I remember nodding my head vigorously with a cheesy smile plastered across my face. Everything she was describing to me was hitting so close to home. I had to have Eli’s product!
It’s no secret that women’s reproductive hormones dictate so much of what goes on in their bodies, from the onset of menstruation, to ongoing ovulation and eventually driving menopause. Every single day a woman is affected due to these changing hormone levels and yet women have no clear mechanism to truly decipher what’s going on (apart from a blood test in a lab).
Through a simple at-home saliva test, Eli’s technology enables women to track and analyze their hormones to help them better understand their entire ovulation cycle. This will be a game changer for women trying to conceive. For women looking for a natural form of contraception. For women wanting to track their moods, or triangulate the cause of headaches. Or for women going through menopause. Honestly, the list is endless.
At its core, Eli is providing women access to their health data in order to drive better health outcomes. Their technology is unlike anything we’ve seen on the market, and we have no doubt that Eli is going to change women’s health as we know it.
You can read more about Eli here or sign up for updates on their launch here.
We are so excited to be on this journey with them, and I’ll personally be first in line as soon as Eli’s product hits the market!
Subscribe to our newsletter
Signup to get quarterly updates and important announcements from 2048 Ventures.
Our Investment in FemTherapeutics
FemTherapeutics is personalizing medicine for women using custom gynecological prosthetics.
Our Investment in Adaptis
Adaptis is an AI-powered modeling platform for improving and optimizing the carbon footprint of existing buildings.
Introducing 2048 Biotech Competition
Introducing 2048 Ventures Biotech Competition. The Biotech Competition gives you an incredible opportunity to kickstart your Biotech venture. The winner of the competition will receive $200K on an uncapped SAFE, and the runner up will get $50K.